Optimal Management of Clostridium Difficile Infection (CDI) and CDI Recurrence in Patients With IBD

Optimal Management of Clostridium Difficile Infection (CDI) and CDI Recurrence in Patients With IBD

On-Demand Webcast

Guideline recommendations are available to inform the selection, intensification, and sequencing of available therapies for the treatment of CDI in patients with IBD. In addition to traditional antibiotic approaches to treatment—whose non-selective mechanisms may lead to poor effects on the underlying microbiome—a first-in-class monoclonal antibody is now available to prevent CDI recurrence by binding to the C. diff toxin B and neutralizing its effects. Recent data demonstrate the benefit of this agent in preventing infection recurrence in high-risk patients who are receiving antibacterial treatment.

The COVID-19 pandemic has generated a unique and pressing challenge to populations with chronic health conditions. While current data suggest that patients with IBD are not more susceptible to infection by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), older individuals and those with underlying conditions, including IBD, are more likely to develop major complications. Clinical panel statements and guidelines are now available for the care of patients with IBD in the COVID-19 era, although the relationship between SARS-CoV-2, IBD, and CDI remains incompletely understood. Common COVID-19 related gastrointestinal (GI) manifestations and large-scale antibiotic use (to combat secondary bacterial infections) raise serious CDI concerns. In particular, patients with COVID-19 who have received antibiotics and/or who experienced GI indications may possess an altered microbiome with reduced colonization resistance against C. diff. These individuals might, therefore, be more susceptible to CDIs. Hence, efforts to optimize treatment should be paired with a shared decision-making approach to support patients’ individual needs. IBD specialists and other gastroenterology professionals require targeted education to overcome current diagnostic and therapeutic challenges in the management of CDI in patients with IBD, including those associated with COVID-19, and to ensure the adoption of evidence-based co-treatment strategies. 



Jessica R. Allegretti, MD, MPH
Brigham and Women's Hospital
Boston, Massachusetts


Ari Grinspan, MD
Mount Sinai
New York, New York
Sahil Khanna, MBBS, MS
Mayo Clinic
Rochester, Minnesota

Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.


This activity is designed and certified for the entire IBD healthcare team and includes education for gastroenterologists, pediatric gastroenterologists, surgeons, physicians, PhDs, researchers, pharmacists, nurse practitioners, physician assistants, gastroenterology nurses, and residents/fellows/students.


After participating in this activity, learners should be better able to:

  • Employ strategies for the timely recognition and initial management of CDI in patients with IBD
  • Evaluate newer therapeutic tactics to treat and prevent CDI recurrence
  • Integrate the latest evidence into protocols for effective management of CDI and IBD in the COVID-19 era

To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: Jan. 4, 2021
Expiration Date: Jan. 4 , 2022 
Estimated Time to Complete: 1.00 hours

There is no fee associated with this activity.


NACCME would like to thank the following company/companies who has/have supported this program through educational grants and/or in-kind support: Merck Sharp & Dohme Corp.



In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this internet enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 1.00 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.00 contact hours. 


American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.


This internet enduring, knowledge-based activity (Universal Activity Number: JA0006201-0000-21-022-H01-P) has been approved for a maximum of 1.00 contact hours (.100 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, NACCME must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. NACCME is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 credit(s). PAs should only claim credit commensurate with the extent of their participation.


This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Planning Committee

In addition to the faculty listed below, NACCME planners and staff include Samantha Conforti, Lara Gray, Damon Harper, Mary Johnson, Kathleen Hines, Randy Robbin and Greaton Sellers. 

All planning committee members have disclosed no relevant financial relationships with any commercial interest.


The faculty have reported the following:


The faculty have reported the following:

Jessica Allegretti: Advisory BoardArtugen, Iterative Scopes; Consultant Finch Therapeutics, Janssen, Pandion, Pfizer, Servatus, Takeda; Grant/Research Support-Merck

Ari Granspan has nothing to disclose

Sahil Khanna has nothing to disclose


North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.


NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.


Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Associate Director, Greaton Sellers,  Accreditation and Compliance, can be requested for a second level of review. Mr. Sellers can be contacted via phone at 609-371-1137, by email at gsellers@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.